This study was designed to assess the efficacy and safety of two immunosuppressant regimens in kidney transplantation based on the administration of @entity1140 -one of them with @entity1140 , @entity500 , and @entity288 (n=239) and the other with @entity1140 , and @entity288 (n=236). After completing the initial 3-month study, the @entity1 remaining in the study (197 and 195, respectively) were assessed for 3 years. The incidence of @entity697 ( @entity697 ) episodes treated during this period was 28.8% with dual-drug therapy and 29.7% with triple-drug therapy. Late @entity697 : episodes between 4 and 36 months were scarce (3.3% in dual and 4.2% in triple therapy). Chronic rejection incidence was 7.7% and 8.9%, respectively. The @entity1 who experienced @entity697 episodes during the first 3 months developed chronic rejection more frequently than those who did not suffer @entity697 . @entity1 survival at 3 years was 95% vs 95.6%, and graft survival was 86.6% vs 86.5% (NS). Doses and blood levels of @entity1140 were similar in the two groups. Adverse effects were similar among both treatment groups. Median SCr was 123.8 micromol/L vs 114.9 micromol/L in @entity1 who did experience @entity697 : 145.9 micromol/L vs 132.6 micromol/L in those with early @entity697 ; and 194.5 micromol/L vs 152 micromol/L in those who presented with late @entity697 . Need for de novo posttransplant insulin was 4.2% in the dual-drug group and 3.8% in the triple-drug cohort. These results demonstrate that, after 3 years of follow up, there were similar efficacy data among the dual- and triple-drug regimens. Thus, addition of @entity500 does not contribute any advantage in the middle term.

Comparison between a two-drug regimen with XXXX and steroids and a triple one with @entity500 in kidney transplantation: results of a European trial with 3-year follow up.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute rejection', 'AR'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']
